Journals / Turkish Journal of Medical Sciences / 2016 / Cilt: 46 - Sayı: 2

Prevalence and related factors of psoriasis and seborrheic dermatitis: a community based study

Pages
303–309
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Whereas SD prevalence varies between 2% and 12% throughout the world, the average SD prevalence was 5.2% in this study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Backgroud/aim: We aimed to determine the prevalence of psoriasis (PS) and seborrheic dermatitis (SD) (erythematous-squamous diseases) in our region and reveal the frequently encountered associated factors to aid in planning appropriate healthcare.
📊
Key Findings & Data:Materials and methods: A community-based study was conducted with 85 sample groups that reflected the population rate and demography of Tokat Province in northern Anatolia.
💡
Conclusion & Impact:Whereas SD prevalence varies between 2% and 12% throughout the world, the average SD prevalence was 5.2% in this study.
🔬Design:Research Article
📍Scope:85 sample
⚙️Variables:Domain Parameters

Abstract

Backgroud/aim: We aimed to determine the prevalence of psoriasis (PS) and seborrheic dermatitis (SD) (erythematous-squamous diseases) in our region and reveal the frequently encountered associated factors to aid in planning appropriate healthcare. Materials and methods: A community-based study was conducted with 85 sample groups that reflected the population rate and demography of Tokat Province in northern Anatolia. Results: In this community, the prevalence of PS in people older than 20 years of age was 1.2% and the prevalence of SD was 5.2%. SD rates were higher in patients who used tobacco and especially alcohol. SD prevalence was also higher in patients treated for depression and epilepsy. Furthermore, as education levels increased, SD prevalence increased proportionally. Conclusion: In general, PS prevalence in this region was higher than in Asia and Africa but lower than in Europe and the United States. Whereas SD prevalence varies between 2% and 12% throughout the world, the average SD prevalence was 5.2% in this study.

🔖

Cite This Article

DEMİR, A. K., KALKAN, G., SEÇKİN, H. Y., TAKCI, Z., ÖNDER, Y., ŞAHİN, Ş., ÇITIL, R., BAŞ, Y. (2022). Prevalence and related factors of psoriasis and seborrheic dermatitis: a community based study. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 2, 303–309. https://ajindex.com/articles/610790

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 559–568
  2. Szepietowski JC, Reich A, Wesołowska-Szepietowska E, Baran E. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009; 52: 357–363
  3. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014; 70: 512–516
  4. Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, Jih JS, Chen CC, Lee DD, Wang WJ et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol 2009; 89: 262–266
  5. Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, Liu Y, Peng G, Zhou J, Xue S et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol 2012; 22: 663–667
  6. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141: 1537–1541. 7. de Avelar Breunig J, de Almeida HL, Duquia RP, Souza PRM, Staub HL. Scalp seborrheic dermatitis: prevalence and associated factors in male adolescents. Int J Dermatol 2012; 51: 46–49
  7. Plunkett A, Merlin K, Gill D, Zuo Y, Jolley D, Marks R. The frequency of common nonmalignant skin conditions in adults in central Victoria, Australia. Int J Dermatol 1999; 38: 901–908
  8. Nanda A, Al-Hasawi F, Alsaleh QA. A prospective survey of pediatric dermatology clinic patients in Kuwait: an analysis of 10,000 cases. Pediatr Dermatol 1999; 16: 6–11
  9. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649–655
  10. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829– 835
  11. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, Meyerovitch J. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol 2008; 22: 585–589
  12. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, Troxel AB. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411–2418
  13. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel AB, Gelfand JM. Psoriasis severity and the prev